Imagion Biosystems Ltd. (AU:IBX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Imagion Biosystems Ltd. is set to boost its MagSense® molecular MRI imaging technology, supported by a $3 million capital raise. The funds will advance clinical development, including a Phase 2 study for its HER2 imaging agent, and extend its technology to prostate and ovarian cancer detection. The company also welcomes Dr. Susan Harvey as a new Medical Affairs Advisor, enhancing its expertise in cancer imaging.
For further insights into AU:IBX stock, check out TipRanks’ Stock Analysis page.